Table 1.
Demographic and perioperative clinical data.
| Normal IMT (n = 221) | Increased IMT (n = 186) | p value | |
|---|---|---|---|
| Sex (female) | 41 (18.6) | 32 (17.2) | 0.724 |
| Age (years) | 62.2 ± 9.8 | 66.3 ± 8.4 | <0.001* |
| BSA (m2) | 1.8 ± 0.2 | 1.7 ± 0.2 | 0.645 |
| DM | 125 (56.6) | 104 (55.9) | 0.896 |
| HTN | 149 (67.4) | 134 (72.0) | 0.313 |
| CVA | 18 (8.1) | 21 (11.3) | 0.283 |
| CKD/preoperative RRT | 35 (15.8)/12 (5.4) | 25 (13.4)/8 (4.3) | 0.497/0.600 |
| EF (%) | 55.4 ± 13.9 | 53.3 ± 15.3 | 0.158 |
| Left main disease | 49 (22.2) | 52 (28.1) | 0.176 |
| Number of graft | 3.4 ± 0.8 | 3.3 ± 0.8 | 0.800 |
| Number of diseased vessels | 2.9 ± 0.4 | 2.9 ± 0.3 | 0.989 |
| 1 vessel disease | 1 (0.5) | 0 | 1.000 |
| 2 vessel disease | 29 (13.1) | 26 (14.0) | 0.884 |
| 3 vessel disease | 191 (86.4) | 160 (86.0) | 1.000 |
| Unstable angina | 126 (57.0) | 98 (52.7) | 0.355 |
| MI within 1 week | 39 (17.7) | 35 (18.8) | 0.777 |
| NYHA III or IV | 24 (10.9) | 28 (15.1) | 0.221 |
| EuroSCORE II | 4.1 ± 2.8 | 4.7 ± 2.7 | 0.051 |
| Beta blocker | 119 (53.8) | 92 (49.5) | 0.426 |
| RAS antagonists | 96 (43.4) | 92 (49.5) | 0.233 |
| Statin | 169 (76.5) | 141 (75.8) | 0.907 |
| Katz grade/grade ≥ 4 | 3.4 ± 0.8/102 (46.2) | 3.7 ± 0.7/117 (62.9) | <0.001*/0.001* |
| Preoperative CK-MB (μg/L) | 2.5 ± 4.6 | 3.2 ± 10.8 | 0.405 |
| Preoperative Cr (mg/dL)/eGFR | 1.3 ± 1.8/80.8 ± 25.9 | 1.2 ± 1.2/79.9 ± 23.2 | 0.208/0.691 |
Values are presented as the mean ± standard deviation or number of patients (%). *p < 0.05.
BSA, body surface area; CKD, chronic kidney disease; CK-MB, serum creatinine kinase-MB level; Cr, serum creatinine level; CVA, cerebrovascular accident; DM, diabetes mellitus; EF, ejection fraction; eGFR (mL·min−1·1.73 m−2), estimated glomerular filtration rate; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; HTN, hypertension; left main disease, left main coronary artery stenosis >50%; MI, myocardial infarction; NYHA, New York Heart Association Functional Classification; RAS, renin-angiotensin system; RRT, renal replacement therapy.